Stock Detail
GILEAD SCIENCES INC
Sector: Biotechnology
Latest Quote @ Wed Jun 6 09:20:36 (15 min delayed)
| $51.84 |
$52.09 |
$51.94 |
+0.00 |
0.00% |
|
Last Day's Data
| $51.94 |
$52.05 |
$0.91 |
1.78% |
0.00 |
$51.03 |
| $50.96 |
$50.87 |
6.00 |
79.23B |
12.06M |
29.08 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 52.80 |
52.37 |
51.62 |
51.19 |
50.44 |
Stock Profile
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for patients suffering from life-threatening diseases primarily in North America, Europe, and Australia. It focuses its research and clinical programs on anti-infectives. The company's products include Viread, Emtriva, and Truvada, which are used for the treatment of human immunodeficiency virus infection in adults; AmBisome, an antifungal agent to treat serious invasive fungal infections caused by various fungal species; Hepsera, which is used for the treatment of chronic hepatitis B infection; Vistide, used for the treatment of cytomegalovirus retinitis; and DaunoXome, a liposomal formulation of the anticancer agent daunorubicin, for the treatment of AIDS-related Kaposi's sarcoma. Its products also comprise Tamiflu, which is used for the prevention and treatment of influenza; and Macugen, for the treatment of neovascular age-related macular degeneration. Gilead sells its products primarily through wholesalers and distributors. The company has collaborative relationships with Bristol-Myers Squibb Company; Achillion Pharmaceuticals, Inc.; EyeTech Pharmaceuticals, Inc.; Fujisawa Healthcare, Inc.; GlaxoSmithKline; Japan Tobacco, Inc.; Pfizer, Inc.; F. Hoffmann-La Roche, Ltd.; and Sumitomo Pharmaceuticals Co., Ltd. Gilead was founded by Michael Riordan in 1987. The company is headquartered in Foster City, California.
